Avtor/Urednik		Černelč, Peter
Naslov		Naše izkušnje zdravljenja bolnikov z dlakastocelično levkemijo s kladribinom
Prevedeni naslov		Follow-up of patients with hairy cell leukemia after treatment with cladribine
Tip		članek
Vir		Zdrav Vestn
Vol. in št.		Letnik 73, št. Suppl 1
Leto izdaje		2004
Obseg		str. I-35-7
Jezik		slo
Abstrakt		Background. The long-term outcome in 16 patients with hairy cell leukemia (HCL) treated with cladribine between 1995 and 2003 is reported. Patients and methods. Cladribine was administered to 13 patients in a dose 0.1 mg/kg/day for 7 days, and the same daily dose was applied once a week for 6 weeks in 3 patients. Their mean age was 57 years (range 32-67) and the male to female ratio 8:1. Four patients had also received a prior therapy with interferon and one was splenectomised. Results. Complete remission (CR) was achieved in 12 (75%) patients and partial remission (PR) in 4 (25%) of cases. With a follow up of 9 years in 12 patients CR lasted between 18 and 88 months (mean 68), 3 (25%) of them relapsed after 54-80 months (mean 71) while 4 patients with PR progressed after 40 to 76 months (mean 63). Six patients had an infection prior to or during the treatnaent. Conciusions. In HCL patients cladribine treatment yields high percentage of CR and durable response, tolerable toxicity and prolonged survival.
Izvleček		Izhodišča. Uspešnost zdravljenja s kladribinom ocenjujejmo pri 16 bolnikih z dlakastocelično levkemijo (DCL) v obdobju od leta 1995 do 2003. Bolniki in metode. Srednja starost bolnikov z DCL je bila 57 let (32-67 let), odnos med moškimi in ženskami je bil 8:1. 4 bolnike smo pred tem zdravili z interferonom alfa, enega pa s splenektomijo. 13 bolnikov je prejemalo kladribin 0,1 mg/kg/ na dan 7 dni, 3 bolniki so dobivali enak dnevni odmerek enkrat na teden 6 tednov. Rezultati. Popolno remisijo bolezni (PR) smo dosegli pri 12 (75%) bolnikih, delno remisijo (DR) pa pri 4 (25%) bolnikih. Po 9 letih ugotavljamo da so bili bolniki v PR od 18 do 88 mesecev (mediana 68), bolezen se je ponovila pri 3 (25% bolnikih, ki so bili v PR od 54-80 mesecev (mediana 71), in pri vseh 4 bolnikih ki so bili v DR od 40 do 76 mesecev (mediana 63). Šest bolnikov je imelo okužbo pred ali med zdravljenjem s kladribinom. Zaključki. Po zdravljenju s kladribinom dosežemo velik delež dolgih PR. Okužbe so glavni zaplet zdravljenja, zato profilaktično dajemo protibakterijska in protiglivična zdravila.
Deskriptorji		LEUKEMIA, HAIRY CELL CLADRIBINE TREATMENT OUTCOME